Comment on

• Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease.

  Gold M. Gold M. J Clin Psychiatry. 2007 Mar;68(3):430-8. doi: 10.4088/jcp.v68n0313. J Clin Psychiatry. 2007. PMID: 17388715
• Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study.

  Huertas D, López-Ibor Aliño JJ, Molina JD, Chamorro L, Balanza J, Jiménez MP, Hornillos M. Huertas D, et al. J Clin Psychiatry. 2007 Mar;68(3):439-44. doi: 10.4088/jcp.v68n0314. J Clin Psychiatry. 2007. PMID: 17388716 Clinical Trial.
• Helping families with end-of-life care in Alzheimer's disease.

  Kettl P. Kettl P. J Clin Psychiatry. 2007 Mar;68(3):445-50. doi: 10.4088/jcp.v68n0315. J Clin Psychiatry. 2007. PMID: 17388717 Review.